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transfusion syndrome (TTTS). In this study, we aimed to document the severity of
fetal cardiac dysfunction in Stage IV TTTS (fetal hydrops) and assess evolution
of cardiac function longitudinally after fetoscopic laser surgery. Methods:
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echocardiograms and neonatal outcomes for 22 cases of Stage IV TTTS
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and 2011. Myocardial performance index, atrioventricular valve flow patterns,
ventricular shortening fraction, ventricular hypertrophy, outflow tract obstruction
and venous Doppler waveforms were assessed. Results Nineteen fetuses
(86.4%) had ascites, eight (36.4%) had pleural effusions, nine (40.9%) had a
pericardial effusion and 12 (54.5%) had subcutaneous edema at presentation.
Preoperatively, cardiac function was grossly abnormal in all. Eight fetuses
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ABSTRACT
Objective Cardiac dysfunction is common in the recipient
fetus of twin–twin transfusion syndrome (TTTS). In
this study, we aimed to document the severity of fetal
cardiac dysfunction in Stage IV TTTS (fetal hydrops) and
assess evolution of cardiac function longitudinally after
fetoscopic laser surgery.
Methods We reviewed obstetric ultrasound examina-
tion data, pre- and postoperative echocardiograms and
neonatal outcomes for 22 cases of Stage IV TTTS
undergoing fetoscopic laser ablation of placental anasto-
moses between 1998 and 2011. Myocardial performance
index, atrioventricular valve flow patterns, ventricular
shortening fraction, ventricular hypertrophy, outflow
tract obstruction and venous Doppler waveforms were
assessed.
Results Nineteen fetuses (86.4%) had ascites, eight
(36.4%) had pleural effusions, nine (40.9%) had a
pericardial effusion and 12 (54.5%) had subcutaneous
edema at presentation. Preoperatively, cardiac function
was grossly abnormal in all. Eight fetuses (36.4%)
had functional pulmonary atresia and one (4.5%)
had functional aortic atresia. Seventy-seven percent
of recipient fetuses survived until birth. Postoperative
echocardiographic follow-up (mean, 26 days) showed that
indices of fetal cardiac function improved considerably,
but never completely normalized. Six of the eight fetuses
with functional pulmonary atresia (75.0%), as well as
the fetus with functional aortic atresia, survived to birth.
In all cases, the functional atresia resolved within 48 h
of laser ablation therapy and none had structural valve
anomalies at birth. All fetal effusions resolved after the
laser.
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Conclusions Fetoscopic laser ablation of placental anas-
tomoses reverses cardiac dysfunction and valvulopathy,
even in the most severe cases of TTTS. However, recovery
takes longer than in early stage disease. Copyright 
2013 ISUOG. Published by John Wiley & Sons Ltd.
INTRODUCTION
Twin–twin transfusion syndrome (TTTS) complicates
9–15% of monochorionic twin pregnancies1,2. The eti-
ology is not fully understood3, but a deregulation of
endocrine factors (including those involved in the renin–
angiotensin system and endothelin-13) in combination
with placental vascular anastomoses connecting the fetal
circulations plays a role in the ‘recipient’ fetus develop-
ing polyuric polyhydramnios, hypertension and cardiac
dysfunction and the ‘donor’ twin developing oligouric
oligohydramnios4–6. Ablation of the communicating
intertwin vessels by fetoscopic laser is the optimal ther-
apy for TTTS7, and normalizes both the oligohydram-
nios/polyhydramnios sequence and the recipient’s cardiac
dysfunction within 6–8 weeks8,9. Although congenital
heart disease is 3–4 times more common after TTTS
than in uncomplicated monochorionic twins10, the long-
term cardiac outcome for recipient fetuses with TTTS is
generally good11.
Approximately 10% of cases of TTTS present at referral
centers at Stage IV (hydrops in the recipient fetus)12,13.
Although this subgroup might behave differently from
those with less advanced stages of TTTS, owing to
the more severe fetal cardiac involvement, large studies
assessing recipient cardiac function in Stage IV disease
and documenting the cardiac response to fetal therapy in
this subpopulation are lacking. Some centers even consider
severe cardiac dysfunction in the recipient as an indication
for selective fetal reduction, rather than laser therapy14,15.
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. ORIGINAL PAPER
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The aim of this study was to report on cardiac and
obstetric outcomes of a large cohort of fetuses with
Stage IV TTTS treated by laser ablation of the placental
vascular anastomoses.
METHODS
This was a retrospective study of all recipient fetuses with
Stage IV TTTS who underwent fetal echocardiography
before and after fetoscopic laser ablation of placental
anastomoses at Mount Sinai Hospital, Toronto, Canada
from February 1998 to October 2011. The study
was approved by the research ethics boards of the
participating centers.
TTTS was defined as oligouric oligohydramnios in
one fetus and polyuric polyhydramnios in the other
of a monochorionic–diamniotic twin pair. Chorionicity
was determined based on first-trimester ultrasound
findings and confirmed on placental pathology after
birth. Polyhydramnios was defined as a deepest vertical
amniotic fluid pocket of > 10 cm after 20 weeks, > 8 cm
between 16 and 20 weeks and > 6 cm before 16 weeks’
gestation. Oligohydramnios was defined as a deepest
vertical amniotic fluid pocket of < 2 cm. TTTS severity
was staged according to Quintero’s criteria13.
Maternal medical records, pre- and postoperative ultra-
sound scans, fetal echocardiograms and postnatal survival
until 6 months of age were reviewed. The majority of fetal
echocardiograms were performed in the fetal cardiology
unit at the Hospital of Sick Children, Toronto, Canada,
but some were obtained from fetal echocardiography
units in other tertiary care referral centers.
Fetal echocardiography was performed by experi-
enced cardiac sonographers with linear and curved array
transducers with variable frequency (3.5–7 MHz) on
high-definition ultrasound machines. All studies included
a complete two-dimensional examination of cardiac
anatomy using standard fetal echocardiographic views
and spectral and color Doppler ultrasound. Frozen images
and clips were stored digitally or on tape. All echocar-
diograms were reviewed retrospectively by two authors
(E.J., T.V.M.) and all measurements were repeated offline.
The following functional parameters were assessed: ven-
tricular hypertrophy (subjective assessment), left and
right ventricular shortening fraction (normal > 31%16),
presence of moderate/severe atrioventricular valve regur-
gitation, monophasic ventricular inflow Doppler pattern,
ratio of ventricular inflow duration over cardiac cycle
length (normal >38%17), left and right ventricular Tei
index, absent or reversed a-wave in the ductus venosus
and presence of umbilical vein pulsations and flow reversal
in the cardiac outflow tracts compatible with (functional)
pulmonary or aortic atresia.
Fetoscopic laser ablation of placental anastomoses
was performed by an experienced surgeon as previously
described, using a sterile technique under local anes-
thesia and intravenous maternal sedation or regional
anesthesia18. A 2-mm 0◦ fetoscope (Karl Storz GmbH,
Tu¨ttlingen, Germany) and a 600-µ laser fiber (Surgical
Laser Technologies Inc., Montgomeryville, PA, USA) were
introduced through a 3.7-mm (11-F) operating sheath and
a 12-F plastic port. Maternal positioning, curved sheaths
and a 70◦ fetoscope (Karl Storz GmbH) were used as nec-
essary for anterior placentae. All visualized anastomoses
were ablated using neodymium:yttrium aluminum garnet
laser energy. At the end of each procedure, amniore-
duction was performed. Postoperatively, antibiotics and
tocolysis (oral and rectal indomethacin ± oral nifedipine)
were continued for 24 h.
Ultrasound examinations to confirm fetal viability and
to exclude recurrent TTTS or twin anemia–polycythemia
syndrome were performed after 24 h, then on a
weekly basis for the first month, and then every 2
weeks for the remainder of the pregnancy. Postoperative
echocardiograms were obtained at 24–48 h, 3 weeks
and 6–8 weeks postoperatively. Infant outcomes were
recorded at birth and at 6 months of age.
Statistical analysis
Descriptive statistics are provided. Distribution of data
was assessed using the D’Agostino and Pearson omnibus
normality test. Pre- and postoperative cardiac functions
were compared using paired t-tests for continuous data
and Fisher’s exact test for nominal data. Cardiac function
in recipient fetuses surviving in utero was compared to
that of non-survivors using t-tests for continuous data and
Fisher’s exact test for nominal data. All tests were two-
sided, and P< 0.05 was considered statistically significant.
RESULTS
Of 316 monochorionic pregnancies undergoing fetoscopic
laser therapy for TTTS in the study period, 34 (10.8%)
were classified as Stage IV. Of these, 12 were excluded as
they did not have complete preoperative cardiac function
assessment. Lack of echocardiography was mainly owing
to the fact that the laser procedure was performed too
soon after the initial ultrasound scan in the fetal medicine
unit to allow for a formal fetal echocardiographic study
to be performed. Gestational age and obstetric ultrasound
findings at presentation in these 12 excluded cases were
similar to those of the included cases (Table 1).
Baseline characteristics for the 22 cases in which
echocardiography was performed prior to intervention
are presented in Table 1. None of the fetuses had a
structural heart defect. As expected, fetal cardiac function
was severely abnormal on first assessment in all cases
(Table 2). Nineteen (86.4%) recipient fetuses had ascites,
eight (36.4%) had pleural effusions, nine (40.9%) had a
pericardial effusion and 12 (54.5%) had subcutaneous
edema. Eight fetuses (36.4%) had echocardiographic
images compatible with functional pulmonary atresia and
one (4.5%) had functional aortic atresia. Two pregnancies
were complicated by ‘maternal mirror syndrome’ and
presented with hypertension, proteinuria and low platelet
counts. One patient required admission to the intensive
care unit owing to severe pulmonary edema.
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 64–69.
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Table 1 Baseline characteristics of study population and excluded
cases in pregnancies with Stage IV twin–twin transfusion syndrome
that underwent laser ablation
Variable
Study
population
(n = 22)
Excluded
cases*
(n = 12)
Maternal characteristics
Age (years) 29.5 (20–37) 31 (25–38)
Parity
0 10 (45.5) 5 (41.7)
1 7 (31.8) 4 (33.3)
> 1 5 (22.7) 3 (25.0)
Ultrasound characteristics
GA first assessment
(weeks)
22.2 ± 3.6 22.7 ± 3.6
Estimated fetal weight (g)
Donor 380 (120–1047) 350 (280–756)
Recipient 585 (150–1655) 418 (350–1373)
Intertwin weight
discordance (%)
35 (1–59) 31 (9–52)
DVP, recipient (cm) 11 (6.3–17.0) 14 (7.5–21)
Abnormal UA flow
Donor
4 (18.2) 4 (33.3)
Recipient 4 (18.2) 4 (33.3)
Absent/reversed DV
a-wave, recipient
20 (90.9) 12 (100.0)
Cervical length at
presentation (mm)
35 ± 9 33 ± 10
Data are expressed as median (range), mean ± SD or n (%).
*Exclusion due to incomplete preoperative cardiac function
assessment. DV, ductus venosus; DVP, deepest vertical amniotic
fluid pocket; GA, gestational age; UA, umbilical artery.
All 22 pregnancies underwent uncomplicated fetoscopic
laser ablation of the placental vascular anastomoses.
Mean amnioreduction volume at the procedure was
1691 ± 820 mL. Postoperatively, cervical cerclage was
performed in one pregnancy, as the cervix measured
< 15 mm.
Pregnancy outcomes for all 22 cases are presented in
Table 3. Ten fetuses (22.7%) died in utero, immediately
after surgery (five donors and five recipients) and two
cases did not have postoperative echocardiography, leav-
ing 15 recipient fetuses that had long-term postoperative
cardiac function assessment. Mean number of follow-up
echocardiograms per pregnancy was 2.2 ± 1 (range, 1–4).
At the time of writing, the last follow-up echocardiogram
was at a median of 26 (range, 1–82) days after the pro-
cedure. As illustrated in Figure 1 and Table 4, all indices
of fetal cardiac function improved considerably after the
laser procedure, yet did not normalize completely within
the observation period. Six of eight fetuses with functional
pulmonary atresia, as well as the fetus with functional
aortic atresia, survived until birth. The functional atresia
resolved in all surviving fetuses, often within the first 48
h after laser therapy. Two fetuses with functional pul-
monary atresia died immediately after the procedure, so
evolution of cardiac function could not be assessed post-
operatively in these cases. All fetal effusions regressed and
eventually disappeared after the laser procedure and both
cases of maternal mirror syndrome resolved completely.
Preoperative fetal cardiac function in recipient fetuses
Table 2 Baseline cardiac function in recipient fetus at first
preoperative assessment in cases of Stage IV twin–twin transfusion
syndrome (n = 22)
Variable Outcome
Right heart function
Absent/reversed a-wave in ductus venosus 20 (90.9)
Umbilical vein pulsations 17 (77.3)
Tricuspid regurgitation 19 (86.4)
Monophasic tricuspid inflow 19 (86.4)
Tricuspid inflow duration/cardiac cycle length (%) 28.7 ± 7.2
Right ventricular hypertrophy 19 (86.4)
Shortening fraction right ventricle (%) 22.1 ± 9.5
Right ventricular Tei index 0.81 ± 0.21
Functional pulmonary atresia 8 (36.4)
Left heart function
Mitral regurgitation 17 (77.3)
Monophasic mitral inflow 13 (59.1)
Mitral inflow duration/cardiac cycle length (%) 35 ± 7
Left ventricular hypertrophy 15 (68.2)
Shortening fraction left ventricle 29.4 ± 6.9
Left ventricular Tei index 0.70 ± 0.16
Functional aortic atresia 1 (4.5)
Data are expressed as mean ± SD or n (%).
Table 3 Pregnancy and fetal outcomes after laser ablation therapy
for Stage IV twin–twin transfusion syndrome
Variable Outcome
Pregnancy outcome (n = 22)
Gestational age at delivery (weeks) 32.7 ± 3.0
PPROM < 37 weeks’ gestation 8 (36.4)
Gestational age at PPROM (weeks) 29.5 ± 4.0
Donor demise 5 (22.7)
Recipient demise 5 (22.7)
Double survival at 6 months of age 11 (50.0)
Single survival at 6 months of age 10 (45.5)
Double demise before 6 months of age 1 (4.5)
Fetal outcome (n = 44)
Recipient birth weight (g) 1789 ± 605
Donor birth weight (g) 1706 ± 498
Intrauterine fetal demise 10 (22.7)
Neonatal demise 2 (4.5)
Overall survival at 6 months of age 32 (72.7)
Data are expressed as mean ± SD or n (%). PPROM, preterm
premature rupture of membranes.
that survived to birth was similar to that in recipients
that died in utero after the laser procedure (Table 5).
Mean gestational age at delivery was 32.7 ± 3.0
weeks. Seven pregnancies (31.8%) delivered before 32
weeks. Mean interval between laser and delivery was
10.6 ± 4.0 weeks. None of the six surviving infants with
functional pulmonary atresia at the time of laser for
TTTS had residual pulmonary stenosis at birth. Two
recipient fetuses died in the neonatal period. The first had
functional pulmonary atresia before laser, which resolved
completely after surgery. The child was born at 27.4
weeks’ gestation and died as a result of the consequences
of prematurity. The other infant was born at 29.1 weeks’
gestation and had more severe respiratory insufficiency
than expected from gestational age alone. This could
potentially have been accounted for by the presence of
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 64–69.
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Figure 1 Longitudinal evolution of echocardiographic parameters in recipient fetus after fetoscopic laser ablation for twin–twin transfusion
syndrome. (a) Right ventricular Tei index (n = 11 fetuses without pulmonary atresia); (b) left ventricular Tei index (n = 14 fetuses without
aortic atresia). , Normal cut-off.
Table 4 Cardiac function in 15 surviving recipient fetuses followed longitudinally after laser surgery for Stage IV twin–twin transfusion
syndrome
Variable Preoperative At last observation P
Right heart function
Abnormal flow in ductus venosus 13 (86.7) 2 (13.3) 0.0001
Umbilical vein pulsations 11 (73.3) 1 (6.7) 0.0005
Tricuspid regurgitation 13 (86.7) 5 (33.3) 0.008
Fusion of tricuspid inflow 12 (80.0) 4 (26.7) 0.009
Tricuspid inflow duration/cardiac cycle length (%) 28.2 ± 8.2 38.6 ± 7.2 < 0.0001
Shortening fraction right ventricle (%) 25.7 ± 6.9 30.5 ± 7.4 0.1
Right ventricular Tei index 0.86 ± 0.23 0.62 ± 0.15 0.02
Functional pulmonary atresia 6 (40.0) 0 (0.0) 0.02
Left heart function
Mitral regurgitation 11 (73.3) 3 (20.0) 0.009
Fusion of mitral inflow 8 (53.3) 0 (0.0) 0.002
Mitral inflow duration/cardiac cycle length (%) 33.7 ± 8.3 37.9 ± 8.1 0.15
Shortening fraction left ventricle (%) 29.6 ± 7.7 30.8 ± 6.7 0.69
Left ventricular Tei index 0.74 ± 0.19 0.55 ± 0.15 0.005
Functional aortic atresia 1 (6.7) 0 (0.0) 1.00
Data are expressed as mean ± SD or n (%).
long-standing pleural effusions in this fetus. Survival
until 6 months of age was 72.7% (32/44 fetuses). Double
survival was seen in 11 pregnancies (50.0%) and survival
of ≥ 1 fetus in 21 pregnancies (95.5%). In our total
cohort of 34 TTTS Stage IV pregnancies (including the
12 pregnancies excluded from the current study owing
to the lack of a prenatal echocardiogram), survival until
6 months of age was 69.1% (47/68 fetuses). Double
survival was seen in 17 pregnancies (50.0%) and survival
of ≥ 1 fetus in 28 pregnancies (82.4%).
DISCUSSION
In the present study, we documented cardiac function in
the recipient fetus of Stage IV TTTS before and after
laser ablation of placental anastomoses. Fetal cardiac
function was severely abnormal at the time of initial
presentation. After therapy, cardiac function improved
at a similar rate to that seen in earlier stages of TTTS,
with dramatic changes within the first 48 h and slightly
slower recovery thereafter9. Given the highly abnormal
preoperative cardiac function, however, resolution takes
longer than in earlier stages of TTTS, and some fetuses
may not recover entirely before birth. This, in addition
to the well known increased incidence of congenital
heart disease in TTTS, which often goes undiagnosed
antenatally, stresses the importance of thorough neonatal
cardiologic follow-up for recipient fetuses of TTTS19,20.
In our study, the rapid improvement in ventricular
function seen in the first 48 h after laser was paralleled by
the resolution of functional pulmonary and aortic atresia
in all cases. As can be expected from a physiological
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 64–69.
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Table 5 Preoperative cardiac function parameters in recipients that survived and those that died following fetoscopic laser ablation of
placental anastomoses for Stage IV twin–twin transfusion syndrome
Variable Survivors (n = 17) Non-survivors (n = 5) P
Right heart function
Absent/reversed a-wave in ductus venosus 15 (88.2) 5 (100.0) 1.00
Umbilical vein pulsations 13 (76.5) 4 (80.0) 1.00
Tricuspid regurgitation 15 (88.2) 5 (100.0) 1.00
Fusion of tricuspid inflow 13 (76.5) 5 (100.0) 0.53
Tricuspid inflow duration/cardiac cycle length (%) 28.7 ± 7.8 28.7 ± 2.9 1.00
Right ventricular hypertrophy 15 (88.2) 4 (80.0) 1.00
Shortening fraction right ventricle (%) 22.6 ± 9.5 20.4 ± 10.4 0.66
Right ventricular Tei index 0.82 ± 0.21 0.72 ± 0.11 0.32
Functional pulmonary atresia 6 (35.3) 2 (40.0) 1.00
Left heart function
Mitral regurgitation 13 (76.5) 4 (80.0) 1.00
Fusion of mitral inflow 10 (58.8) 4 (80.0) 0.61
Mitral inflow duration/cardiac cycle length (%) 34.0 ± 7.9 36.8 ± 3.3 0.48
Left ventricular hypertrophy 12 (70.6) 3 (60.0) 1.00
Shortening fraction left ventricle (%) 29.6 ± 7.5 28.6 ± 5.2 0.78
Left ventricular Tei index 0.73 ± 0.17 0.63 ± 0.09 0.25
Functional aortic atresia 1 (5.9) 0 (0.0) 1.00
Data are expressed as mean ± SD or n (%).
point of view, fetal effusions took longer to resolve, but
ultimately all disappeared. This is in line with a previous
study looking at the evolution of hydrops after fetoscopic
laser surgery in 16 pregnancies complicated by Stage IV
TTTS21.
The presence of functional pulmonary or aortic atresia
before fetoscopic laser surgery was unrelated to fetal
survival or postnatal outflow tract pathology. Indeed,
none of the fetuses with functional pulmonary atresia
prior to laser had residual outflow tract obstruction at
birth. This corroborates the observations of Gray et al.21,
who reported that none of five fetuses with Stage IV
TTTS and functional pulmonary atresia had evidence of
right ventricular outflow tract obstruction on neonatal
echocardiography before laser. Similarly, Moon-Grady
et al.22 reported that two of three fetuses with functional
pulmonary atresia prior to laser had normal pulmonary
valves on follow-up and that there was no association
between the severity of fetal pulmonary stenosis or
pulmonary insufficiency and postnatal pulmonary valve
pathology. The lack of association between severity
of prenatal disease and postnatal outcome could lead
one to speculate that the duration, rather than the
severity, of prenatal cardiac involvement impacts on
long-term valve development. The latter speculation,
however, contradicts the observation that the incidence
of pulmonary obstruction at birth in recipient twins
following laser (4–7.8%)11,19,20 was similar to that
in recipient fetuses managed with amnioreduction
(7.5%)23, where the effects of TTTS on the fetuses
are more protracted. Further large follow-up studies
with systematic antenatal and neonatal echocardiography
in recipient fetuses of TTTS are required to identify
predictors of pulmonary valve disease at birth.
Similarly, follow-up studies are required to assess
the impact of the severe cardiac dysfunction seen
in Stage IV TTTS on postnatal neurological outcome.
Indeed, severe cardiac impairment can lead to decreased
end-organ perfusion, and the neurological outcome for
Stage IV TTTS fetuses could be worse than outcomes
for fetuses with earlier stage disease. This theory is
further substantiated by the 6-year follow-up analysis
of the randomized Eurofetus trial, which compared
amnioreduction to laser24, and by a large cohort study
showing a trend towards more neurodevelopmental
impairment with increasing Quintero stage25.
Finally, our study confirmed the high survival rates
previously reported for Stage IV TTTS12. Indeed, overall
neonatal survival in our series was 69.1%, with at least
one infant surviving until 6 months of age in 82.4% of
cases, and both infants surviving in 50.0%. The rate of
fetal demise was similar in donors and recipients; recip-
ients with functional outflow tract atresia had a survival
rate similar to those without atresia and preoperative
cardiac function in recipient fetuses that died was compa-
rable with that in those that survived, which suggests that
demise of the recipient fetus is unrelated to the severity
of cardiac dysfunction. However, the relatively small
number of recipient deaths in the current series limits the
strength of conclusions from these findings.
The dissociation between cardiac dysfunction and
survival rate, in combination with the high rate of
double survival, suggests that selective fetal reduction,
with an inherent maximum survival of 50%, should not
be considered as the therapy of choice for Stage IV TTTS.
In our experience and that of others12, survival in Stage IV
TTTS cases was better than in Stage III TTTS, where
cardiac function in the recipient can similarly improve,
but the donor often has to face the additional challenge
of severe placental discordance.
The most important limitation of our study is the lack
of longer-term follow-up in some of the cases. This was
due to the retrospective study design, the occurrence of
complications inherent to the disease (such as fetal demise
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 64–69.
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and preterm delivery) and the very large geographic
referral pattern of our patients, which precluded on-
site follow-up. Secondly, we only included 22 of 34
pregnancies with Stage IV TTTS in this analysis. The
primary reason for this was the lack of preoperative
echocardiography in the remaining 12 cases, which was
largely due to logistical scheduling issues at the time of
presentation, and should not have induced any significant
bias. Moreover, obstetric characteristics in cases that were
included and excluded were similar. A strength of this
study is that it is the largest to date reporting on the
cardiac changes in Stage IV TTTS following fetal therapy.
In conclusion, recipient fetuses in Stage IV TTTS
have severely altered cardiac function, leading to
functional pulmonary and aortic atresia. Laser ablation of
communicating placental vessels enables cardiac function
to improve and functional atresia and effusions to reverse.
Recipient demise is unrelated to the severity of cardiac
impairment. Further studies are necessary to assess the
impact of transiently impaired cardiac function on longer-
term neurodevelopment. In the absence of these data, we
do not consider Stage IV TTTS as an indication for
selective fetal reduction.
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